

GLOBAL ACADEMIC RESEARCH INSTITUTE

COLOMBO, SRI LANKA



GARI International Journal of Multidisciplinary Research

ISSN 2659-2193

Volume: 06 | Issue: 05

On 31st December 2020

<http://www.research.lk>

Author: Sachimi Draupadi Thrikawala, Upeka Bandaranayake

BMS, School of Science, Sri Lanka

GARI Publisher | Medicinal Plant | Volume: 06 | Issue: 05

Article ID: IN/GARI/ICHM/2020/161 | Pages: 33-47 (15)

ISSN 2659-2193 | Edit: GARI Editorial Team

Received: 07.10.2020 | Publish: 31.12.2020

DETECTION AND DETERMINATION OF ANTIBACTERIAL ACTIVITY OF CYMBOPOGON NARDUS (CITRONELLA) ETHANOLIC EXTRACT AGAINST ESCHERICHIA COLI AND STAPHYLOCOCCUS AUREUS

Sachimi Draupadi Thrikawala, Upeka Bandaranayake

School of Science, Business Management School, Sri Lanka

ABSTRACT

Finding alternative treatments for bacterial infections due to the increase of antibiotic resistance is currently a major global challenge and discovery of phytochemicals with antibacterial potential is highly relevant. *Cymbopogon nardus* (Citronella) plant species has evidenced of having antibacterial property from previous research studies. This study was aimed to assess the antibacterial activity of phytochemical compounds of *C. nardus* ethanolic extract against *Escherichia coli* (ATCC 25922) and *Staphylococcus aureus* (ATCC 25923) bacterial strains. Antibacterial activity was assessed using in vitro antibacterial tests. Antibiotic susceptibility test (ABST) was the qualitative test conducted to determine zones of inhibition against bacterial species at 50 and 100 mg/ml concentrations. Highest zone diameters were exhibited against *S. aureus* as 15.67 ± 0.58 mm and 16.67 ± 0.58 mm respectively. Inhibition diameters detected against *E. coli* were 15.00 ± 0.00 mm and 15.33 ± 1.15 mm respectively. Antibacterial activity expressed by *C. nardus* was significantly different between bacterial species. Broth dilution method was conducted as quantitative antibacterial tests to detect Minimum Inhibitory Concentrations (MIC). Lowest concentration of *C. nardus* with bacteriostatic potential against *S. aureus* was detected as 12.50 mg/ml and against *E. coli* was detected as 25 mg/ml.

Minimum Bactericidal Concentrations (MBC) for *S. aureus* and *E. coli* were detected as 50 and 100 mg/ml respectively. The data from present study confirmed the presence of antibacterial compounds and the promising aspect of *C. nardus*. The discovered therapeutic potential of *C. nardus* as an antibacterial agent against *E. coli* and *S. aureus* needs to be fully evaluated using further studies.

Keywords: *Cymbopogon nardus* (Citronella), Antibacterial activity, Antibiotic susceptibility test, bacteriostatic, Bactericidal

INTRODUCTION

Background

Antibacterial activity is killing or inhibiting the growth of bacteria without harming nearby tissues (Singh et al., 2019; Ventola, 2015). Antibiotics are drugs used for achieving this purpose. But due to the extensive use and misuse of antibiotics, bacteria can change their response to certain antibiotics. As a result, bacteria develop resistance against those antibiotics, which is posing a major global health care problem currently (Elisha et al., 2017; Ventola, 2015). Medicinal plants have been used in folk medicine to treat bacterial diseases (Cheesman et al., 2017). Therefore, some studies have been conducted to discover novel compounds with antibacterial properties from plant species as an alternative approach in the

wake of increasing antibiotic resistance. Treatments with medicinal plants have shown that they are less expensive with fewer side effects. Secondary metabolites of plants, such as tannins, alkaloids, flavonoids, lactones, terpenoids, steroids, glycoside, coumarins and quinones are identified as substances with antimicrobial potential (Abadallah and Ali, 2019; Cheesman et al., 2017; Elisha et al., 2017). However, medicinal plants could be more suited to treat non-severe infections because of the relatively weak defense activity and non-specificity (Cheesman et al., 2017).

Escherichia coli and Staphylococcus aureus bacterial species.

Escherichia coli and *Staphylococcus aureus* are bacterial species of human normal flora (Bajaj, Singh and Viridi, 2016; Sannasiddappa et al., 2011). *E. coli* is gram-negative, rod-shaped bacterium located in human gastrointestinal tract (Tanih et al., 2015). Certain serotypes can cause infectious diseases including urinary tract infections, diarrheal diseases, septicemia, meningitis and pneumonia (Peirano et al., 2018; Lee, Lee and Choe, 2018; Fratamico et al., 2016; Kim, 2016; Jafri et al., 2014). β -lactams, fluoroquinolones and trimethoprim-sulfamethoxazole are the antibiotics used for *E. coli* infections. β -lactams, such as ampicillin, amoxicillin and cephalosporin bind with penicillin binding protein (PBP) to lead the inhibition of peptidoglycan cell wall synthesis (Stohr et al., 2020; Alanazi, Alqahtani and Aleanizy, 2018; Kapoor, Saigal and Elongavan, 2017; Vranic, and Uzunovic, A, 2016; Park et al., 2012). However, *E. coli* build up the ability to hydrolyze β -lactam ring with the production of β -lactamase enzyme (Zeng and Lin, 2013). Fluoroquinolones primarily targets enzyme DNA gyrase in *E. coli* which catalyzes DNA negative supercoiling (Terahara and Nishiura, 2019; Kapoor, Saigal and Elongavan, 2017). The increase in resistance is due to

the development of mutations in *gyrA* subunit of gyrase and in addition, it induces mutation in *parC* subunit of topoisomerase IV, enzyme nicks and separate daughter DNA strand after the replication (Karczmarczyk et al., 2011; Stone et al., 2003). Trimethoprim-sulfamethoxazole is a combination of sulfonamide and trimethoprim involve in inhibition of distinct steps of tetrahydrofolic acid (THF) synthesis (Gangcuangc6 et al., 2015; Masters et al., 2003). Sulfonamide inhibits the enzyme dihydropteroate synthase (DHPS) which synthesizes dihydropteroate from para-aminobenzoate (de Castro Spadari et al., 2020). Trimethoprim involves in the inhibition of the catalytic activity of dihydrofolate reductase (DHFR) and the production of THF from dihydrofolic acid (Fairhurst and Wellem, 2015; Capasso and Supuran, 2014). Resistance could be induced by overproducing DHFR and cause mutations in the target enzymes (Eliopoulos and Huovinen, 2001). In addition, drug efflux pump in *E. coli* contribute to the enhance of resistance (Soto, 2013; Webber and Piddock, 2003).

Staphylococcus aureus is gram-positive, opportunistic bacteria generally located in human nose and pharynx (Kuraitis and Williams, 2018; Brugger, Bomar and Lemon, 2016). It causes food poisoning and infections in pulmonary, endocarditis, osteoarticular, skin and soft tissues (Tong et al., 2015; Treangen et al., 2014; Parker and Prince, 2011). β -lactam penicillin was used to treat the infections. *S. aureus* showed the resistance to penicillin with the production of β -lactamase by showing the similar resistance mechanism of *E. coli* (Guo et al., 2020; Foster, 2017). Methicillin, β -lactamase resistant antibiotic was developed to reduce above resistance mechanism (Llarrull, Fisher and Mobashery, 2009). However, *S. aureus* developed the resistance to methicillin by encoding modified PBP by *mecA* gene,

known as PBP2a (Foster, 2017; Raġbetli et al., 2016; Llarrull, Fisher and Mobashery, 2009). Methicillin-resistant *S. aureus* (MRSA) causes nosocomial infections (Tong et al., 2015; Šiširak, Zvizdić and Hukić, 2010). Currently, methicillin has been superseded by glycopeptide antibiotic vancomycin (Schweizer et al., 2011). Novel researches have been shown the resistance development against vancomycin within *S. aureus* by altering cell wall biosynthesis and homeostasis (Gardete and Tomasz, 2014; Loomba, Taneja and Mishra, 2010).

Cymbopogon nardus (Citronella).

Cymbopogon nardus is perennial, aromatic, tropical plant belonging to Poaceae family. It is cultivated in tropical and subtropical regions and native to Southeast Asia, such as India, Burma, Sri Lanka, Indonesia and Java (Muttalib et al., 2018; De Toledo et al., 2016). *C. nardus* is categorized as a medicinal plant. It is used to cure intestinal parasite infections, digestive and menstrual problems, rheumatism and fever (Sabuna et al., 2018; Subramanian et al., 2015; Abena et al., 2008). Essential oil of *C. nardus* is commonly used as a repellent against *Aedes aegypti* and *Culex quinquefasciatus* (Sritabutra and Soonwera, 2013). Antimicrobial, Antibacterial, antifungal and antioxidant activities of *C. nardus* have been found from previous studies (Pontes et al., 2018; Kačániová et al., 2017; Subramanian et al., 2015). *C. nardus* is abundant with citronellal, geraniol and citronellol monoterpenes, elemol and naphthalene phytochemicals which have been recognized as antibacterial agents (Sabuna et al., 2018; Bhattamisra et al., 2018; Lopez-Romero et al., 2015). Wei and Wee (2013) has shown that essential oil of *C. nardus* has high potential to use as an antibacterial agent against systemic bacteria of aquatic animals. According to the study of Wibowo et al. (2018), *C. nardus* essential oil has antibacterial

activity against both positive and negative bacteria. Pontes et al. (2018) discovered the antimicrobial activity and antibiofilm activity of *C. nardus* essential oil and geraniol. The research of Kamal et al. (2020) has proved the antimicrobial activity of *C. nardus* essential oil and its volatile compounds against oral pathogens.

According to the evidences of previous research studies, *C. nardus* has been shown positive results as an antibacterial agent against certain bacterial species. Therefore, ethanolic extracts of *C. nardus* could potentially show antibacterial activity against *E. coli* and *S. aureus*. This study is aimed to determine the antibacterial activity of ethanolic extract of *C. nardus* and detect its effectiveness against *E. coli* and *S. aureus*.

METHODOLOGY

Bacterial strains.

Stock cultures of bacterial strains *Escherichia coli* (ATCC 25922) and *Staphylococcus aureus* (ATCC 25923) were obtained from Medical Research Institute, Sri Lanka and subcultures were maintained in BMS laboratory under refrigeration. Fresh overnight cultures were prepared from subcultures before conducting each experiment.

Plant sample preparation.

C. nardus plant was collected from the cultivation of 'Citro' essential oil (Pvt) LTD, Katuwana, Hambanthota.

Aerial part of *C. nardus* was washed using mineral water, distilled water and disinfected using 70% ethanol. It was dried under the shade with exerted pressure continuously for 7 days.

Dried *C. nardus* sample was pulverized into fine powder by using electric spice grinder (Panasonic) and was refrigerated by storing in red cap vials.

Plant extract preparation.

About 20g of the powdered form of *C. nardus* sample was macerated with 50ml of 95% ethanol. Sample was placed on the roller mixer (KJMR-II) for 48hrs with constant shaking. It was filtered and filtrate was kept in the fume hood (BIOBASE, FH1000) for the ethanol evaporation. Dried extract was weighed and reconstituted to 200 mg/ml concentration using Dimethyl sulfoxide (DMSO) prior to the experimentation procedures (Abdulla et al., 2019; Abadallah and Ali, 2019; Sabuna et al., 2018).

Preparation of bacterial subcultures and diluted suspension of bacterial cultures.

Luria-Bertani (LB) broth was prepared according to the manufacturer's instructions (HiMedia). Approximately 15ml of LB broth was introduced to two 150 ml conical flasks. Three loops of the bacterial culture taken from certain stock culture were inoculated to each media and were incubated at overnight at 37°C.

Diluted bacterial suspensions were prepared by inoculating bacteria taken from overnight cultures into distilled water by visually comparing the turbidity with 0.5 McFarland standard.

Antibacterial susceptibility testing using well diffusion technique.

The protocol is modified from Abadallah and Ali, 2019. Mueller Hinton agar plates were prepared, based on the manufacturer's instructions (HiMedia). Diluted bacterial suspension was inoculated onto the surface of the plates using a sterile swab stick. Four wells of 8mm diameter were bored into the media by using sterilized 1000 µl of micropipette tips. About 50 µl of 50 and 100 mg/ml concentrated reconstituted samples, Negative Control-Distilled water and positive control-1 mg/ml Gentamicin were added into four wells as shown in figure 1. Plates were incubated overnight at 37 °C.

Zones of inhibition were observed and diameters were measured.




Figure 1. Layout of prepared petri dishes for the well diffusion. 50 mg/ml and 100 mg/ml concentrated ethanolic extract, Gentamicin as positive control and distilled water as negative control were introduced to the wells.

Determination of Minimum Inhibitory Concentration (MIC).

The procedure was performed according to protocols by Abdulla et al., 2019; Abadallah and Ali, 2019; Subramanian et al. 2015. Minimum Inhibitory Concentration (MIC) was determined by two-fold broth dilution method. Test tubes were labeled and 1 ml of Mueller Hinton Broth (HiMedia), prepared according to manufacturer's instructions was introduced into each tube. 100 µl of diluted bacterial suspension was inoculated into the broth (Six tubes were prepared for broth dilution test of each bacterial strain). About 1 ml of 200, 100, 50, 25, 12.50 and 6.25 mg/ml concentrated reconstituted ethanol extract was added to the tube series respectively to final concentrations of 100, 50, 25, 12.50, 6.25 and 3.125 ml. Positive controls were prepared for each bacterium by adding 250 µl of 1mg/ml gentamicin into seeded broth. Negative controls were prepared with only seeded broth. In addition, a media control was prepared containing only the broth to check sterility. Prepared tubes were incubated overnight at 37 °C.

Turbidity of each tube was observed with controls and detected the lowest concentration of extract which had shown absence of turbidity.

Determination of Minimum Bactericidal concentration (MBC).

The experiment was performed according to protocols explained by Abdulla et al., 2019; Abadallah and Ali, 2019; Subramanian et al., 2015. Tryptone soy agar (HiMedia) plates were prepared according to manufacturer's instructions. Above MIC test samples with higher concentrations than the MIC value were selected and were streaked on agar media by using quadrant streaking method. Plates were incubated overnight at 37°C. The plates which had shown absence of growth of colonies or one or two colonies were selected and the respective concentrations were determined as the MBC.

Statistical analysis.

All the results of ABST were recorded and were statistically analyzed using IBM SPSS statistics version 21. The data was expressed as mean \pm standard deviation. The significant differences between bacterial species and concentrations and interaction between bacterial species and concentrations were determined by using Two-way ANOVA test.

RESULTS

Results of Antibiotic Susceptibility Test (ABST).

Inhibition zones were detected from *C. nardus* ethanolic extract against both *E. coli* and *S. aureus* bacterial species. Following table 1 shows the zones of inhibition as mean \pm standard deviation of *C. nardus* ethanolic extract against each bacterial species.

Table 1. Zones of inhibition of *C. nardus* ethanolic extract for each bacterial species.

Concentrations (mg/ml)	Zones of inhibition (mean \pm standard deviation) of bacterial species (mm).	
	<i>E. coli</i>	<i>S. aureus</i>
50	15.00 \pm 0.00	15.67 \pm 0.58
100	15.33 \pm 1.15	16.67 \pm 0.58

Below figure 2 shows the plate pictures of three replicates of ABST against each bacterial species.




Figure 2. ABST results of three replicates of *C. nardus* ethanolic extract against both *E. coli* and *S. aureus*. Inhibition zones of all three replicates, conducted for *E. coli* and *S. aureus* species were presented as mean \pm standard deviation. 1, 2, 3- replicate number. A-50 mg/ml, B-100 mg/ml, C-Positive control and D-Negative control. Mean value of positive controls of *E. coli* was 24.00 \pm 2.00 mm and *S. aureus* was 26.00 \pm 1.73 mm. Inhibition zones were absent in negative controls.

According to the graph of figure 3, mean values of inhibition zones were increased from 50-100 mg/ml concentrations. Mean values of both 50 and 100 mg/ml concentrations of *S. aureus* were higher than mean values of *E. coli*.




Figure 3. Antibacterial activity of *C. nardus* ethanol extract against *E. coli* and *S. aureus*. The blue bars indicate 50 mg/ml and the green bars indicate 100 mg/ml. The data represent mean \pm SD for three replicates.

Statistical analysis of the plant extracts.

Table 2 shows the Two-way ANOVA analysis of *C. nardus* ethanolic extract against *E. coli* and *S. aureus* at 50 and 100 mg/ml concentrations.

Table 2. Two-way ANOVA analysis of *C. nardus* extract.

Dependent Variable: Inhibition zones

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	4.667 ^a	3	1.556	3.111	.089
Intercept	2945.333	1	2945.333	5890.667	.000
Bacterial_species	3.000	1	3.000	6.000	.040
Concentration	1.333	1	1.333	2.667	.141
Bacterial_species* Concentration	.333	1	.333	.667	.438
Error	4.000	8	.500		
Total	2954.000	12			
Corrected Total	8.667	11			

a. R Squared = .538 (Adjusted R Squared = .365)

Profile plot of figure 4 shows the statistical significance and interaction of concentrations and bacterial strains on estimated marginal means of inhibition zones.




Figure 4. Profile plot of the Two-way ANOVA analysis of *C. nardus*.

According to the analysis, antibacterial activity of *C. nardus* extract showed significant difference ($P < 0.05$) between bacterial species but did not show any significance between concentrations and interaction between concentrations and bacterial species. The bacterial strains used have an observable main effect in relation to the plant samples.

Results for Minimum Inhibitory Concentrations (MIC).

Minimum inhibitory concentrations (MIC) were detected *C. nardus* ethanolic extracts against for both *E. coli* and *S. aureus*. Following table 3 shows the MIC results of *C. nardus* ethanolic extract against each bacterial species.

Table 3. Detected MIC results of *C. nardus* ethanolic extracts against each *E. coli* and *S. aureus* species.

Bacterial species	Concentrations (mg/ml)					
	100	50	25	12.50	6.25	3.125
<i>E. coli</i>	-	-	-	+	+	+
<i>S. aureus</i>	-	-	-	-	+	+

Key - No visible growth + Visible growth

According to the results of MIC test, 25 mg/ml concentration was detected as MIC against *E. coli* and 12.50 mg/ml concentration was detected as the MIC against *S. aureus*.

Following figure 5 includes the three replicates of broth dilution test.




Figure 5. Results of three replicates of broth dilution test, conducted to detect MIC values against *E. coli* and *S. aureus*. MIC of *C. nardus* ethanolic extract against *E. coli* and *S. aureus* was detected from the 2-fold serial dilution with 100, 50, 25, 12.50, 6.25 and 3.125 mg/ml concentrations. 1, 2, and 3 represent the replicate number. (+) - Positive control and (-) – Negative control. Sterile media was used to detect media sterility. + represents the tubes with visible bacterial growth and – represents the tubes with non-visible bacterial growth. According to the replicates, 25 mg/ml concentration was detected as MIC against *E. coli* and 12.50 mg/ml concentration was detected as MIC against *S. aureus* from all three replicates.

Results for Minimum Bactericidal concentration (MBC).

MBCs of *C. nardus* ethanolic extract were determined against both *E. coli* and *S. aureus* species. Table 4 shows the MBC results of both *E. coli* and *S. aureus*.

Table 4. Detected MBC results of *C. nardus* ethanolic extract against each *E. coli* and *S. aureus* species.

Bacterial species	Concentrations			
	100	50	25	12.50
<i>E. coli</i>	-	-	+	+
<i>S. aureus</i>	-	-	-	+

Key + more than two colonies – no growth of colonies or 1 or 2 colonies

According to the table 4, 100 mg/ml concentration was observed as the MBC against *E. coli*. The MBC against *S. aureus* observed as 50 mg/ml.

Figure 6 includes images of plates detected as MBC against *E. coli* and *S. aureus*.




Figure 6. Plates detected MBC of *C. nardus* ethanolic extract against *E. coli* and *S. aureus*. A- Plate of 100 mg/ml detected as MBC against *E. coli*. B -Plate of 50 mg/ml detected as MBC against *S. aureus*

DISCUSSION

The ethanolic extract of *C. nardus* exhibited antibacterial property against both *E. coli* and *S. aureus* from all in vitro antibacterial tests. The results showed that *S. aureus* was most susceptible towards *C. nardus* ethanolic extracts compared to *E. coli*.

Inhibitory effect of *C. nardus* ethanolic extract determined by ABST showed distinctly higher antibacterial effect for *S. aureus* than *E. coli*. However, the inhibitory effect was not distinctly increase between 2-fold increases of concentration values. The research of Kamari et al. (2018), had found zones of inhibition as 14 ± 0.3 mm against *S. aureus* and 18 ± 0.5 mm against *E. coli* for the concentration of $15 \mu\text{l}/\text{disk}$ of *C. nardus* essential oil. Brugnera, Oliveira and Piccoli (2011) had detected 5.37 ± 1.16 and 8.03 ± 1.92 mm zones of inhibition respectively for 500 $\mu\text{l}/\text{ml}$ concentration. Similar study had discovered minimum concentration of *C. nardus* with bacteriostatic potential (MIC) as 3.90 $\mu\text{l}/\text{ml}$ and 7.81 $\mu\text{l}/\text{ml}$ concentrations

against *E. coli* and *S. aureus* respectively. Research of Wibowo et al. (2018) had observed 500 $\mu\text{g}/\text{ml}$ concentration as MIC against *E. coli*, whereas MIC against *S. aureus* was detected as 1000 $\mu\text{g}/\text{ml}$. Additionally, the study had discovered the MIC against Methicillin-resistant *S. aureus* (MRSA) as 2000 $\mu\text{g}/\text{ml}$. Pontes et al. (2018) had conducted a study to observe the antibiofilm activity of *C. nardus* essential oil. According to the study, *C. nardus* had expressed 41 ± 0.94 mm of inhibitory activity against biofilms of *S. aureus* at the concentration of 18mg/ml. However, the study had not showed the inhibitory effect against the biofilms of *E. coli*. Furthermore the study was discovered the bacteriostatic effect of *C. nardus* against *S. aureus* biofilm at the concentration of 0.5 mg/ml and bactericidal effect at the concentration of 4 mg/ml. Bacteriostatic and bactericidal activity against biofilms of *E. coli* was determined as higher than 8 mg/ml. Present study proved the antibacterial activity of *C. nardus* ethanolic extract is relatively lower than its essential oil. Low yield of phytochemical extraction than essential oil could be the reason for lesser activity observed (Wei and Wee, 2013). In addition, composition of phytochemical compounds often differs according to the climate changes, soil composition and extraction methods (Kamal et al. 2020; De Zoysa et al., 2019; Kamari et al. 2018).

Monoterpenes (Citronellal, geraniol and citronellol) found from *C. nardus* show toxic effect for the structural and function of bacterial cell membrane. Monoterpenes interact with the cell membrane of bacteria due to its lipophilic character. This leads expansion of cell membrane, increase of membrane permeability and fluidity, disturbance of membrane-embedded proteins, respiratory inhibition and abnormality of ion transport process (Bouyahya et al., 2019; Trombetta et al., 2005).

Causes of showing lower susceptibility of gram-negative bacteria (*E. coli*) than gram-positive bacteria (*S. aureus*) could be inherent tolerance, structure of bacteria and how the chemical composition of plants affects above parameters. Previous studies have found outer peptidoglycan layer of gram-positive bacterial cell wall makes more permeable for phytochemicals than outer lipopolysaccharide layer of gram-negative bacterial cell wall. Due to the above reason, most of the antimicrobial substances have failed to penetrate through lipopolysaccharide layer of gram-negative bacteria. However, some have displayed the ability to penetrate by breaking the lipopolysaccharide layer (Breijyeh, Jubeh and Karaman, 2020; Koohsari et al., 2015; Brugnera, Oliveira and Piccoli, 2011).

CONCLUSION

The study revealed ethanol extract *C. nardus* possess effective antibacterial property against both *E. coli* and *S. aureus* strains. According to the results of this study, *C. nardus* contains compounds that can be used as antibacterials which serve as alternative treatments for less severe bacterial infections.

As future works, optimization of the extraction of phytochemicals could be done by altering the solvent such as aqueous, methanol, acetone, petroleum ether, benzene and chloroform with different percentages or essential oil synthesis according to the polarity difference (Abiramasundari, Devi and Jeyanthi, 2017). Identification and isolation of phytochemical could be performed by using qualitative phytochemical analysis, high-performance liquid chromatography (HPLC), gas chromatography (GC) or gas chromatography-mass spectrometry (GC-MS) (Ezeonu and Ejikeme, 2016; Subramanian et al., 2015; Chai et al.,

2014). Analysis of the antibacterial activity using other in vitro studies, such as conducting MTT assay to assess bacterial cell viability after treated with the extract (Rai et al, 2018). In addition, studies to evaluate antibiofilm activity of extract could be proceeded (Aka, 2015). All the studies can also be performed for other bacterial strains and clinical isolates to verify the full antibacterial spectrum (Balouiri, Sadiki and Ibsouda, 2016).

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to my supervisor Ms. Upeka Bandaranayake for providing her invaluable guidance, comments and suggestions throughout the project.

Secondly, I would like to thank Dean of Biomedical and Biotechnology in BMS, Dr. Mathi Kandiah for her motivation and guidance.

Lastly, I would like to thank my parents for their help and encouragement to carry out this project.

REFERENCES

- Abadallah, M.S. and Ali, M. (2019), "Antibacterial Activity of *Moringa oleifera* Leaf Extracts against Bacteria Isolated from Patients Attending General Sani Abacha Specialist Hospital Damaturu", *Journal of Applied Pharmaceutical Science*, 1(1), ResearchGate [Online]. Available at: https://www.researchgate.net/publication/332013718_Antibacterial_Activity_of_Moringa_Oleifera_Leaf_Extracts_against_Bacteria_Isolated_From_Patients_Attending_General_Sani_Abacha_Specialist_Hospital_Damaturu (Accessed:30 March 2020).
- Abdulla, E.H., Abdoun, M.A., Mahmoud, W.S. and Alhamdani, F. (2019), "Antibacterial Activity of Crude *Cinnamomum zeylanicum* Ethanol Extract on Bacterial Isolates from Orofacial Infections", *Acta Scientifica Dental Sciencs*, 3(8), pp. 58-63.

- [Online]DOI:
10.31080/ASDS.2019.03.0595.
(Accessed:14April2020).
- Abena, A., Gbenou, J., Yayi, E., Moudachirou, M., Ongoka, R., Ouamba, J. and Silou, T. (2008), "Comparative Chemical and Analgesic Properties of Essential Oils of *Cymbopogon nardus* (L) Rendle Of Benin And Congo", *African Journal of Traditional, Complementary and Alternative Medicines*, 4(3), p.267. [Online]DOI: 10.4314/ajtcam.v4i3.31218. (Accessed: 12 April 2020).
- Abiramasundari, P.P., Devi, S.G. and Jeyanthi, G.P. (2017), "antibacterial activity of the leaves, bark, seed and flesh of *moringa oleifera*", *International journal of Pharmaceutical sciences and research*, 1230. [Online]Available at: <https://ijpsr.com/bft-article/antibacterial-activity-of-the-leaves-bark-seed-and-flesh-of-moringa-oleifera/?view=fulltext> (Accessed:17 August 2020).
- Aka, S.T. (2015), "Killing efficacy and anti-biofilm activity of synthetic human cationic antimicrobial peptide cathelicidin hCAP-18/LL37 against urinary tract pathogens", *Journal of Microbiology and Infectious Diseases*, 5(01), pp15-20. [Online]DOI: 10.5799/ahinjs.02.2015.01.0168.
- Alanazi, M.Q., Alqahtani, F.Y. and Aleanizy, F.S. (2018), "An Evaluation of *E. coli* in Urinary Tract Infection in Emergency Department at KAMC in Riyadh, Saudi Arabia: retrospective study", *Annals of Clinical Microbiology and Antimicrobials*, 17(1). [Online]DOI: 10.1186/s12941-018-0255-z.
- Bajaj, P., Singh, N.S. and Viridi, J.S. (2016), "Escherichia coli β -Lactamases: what really matters", *Frontiers in Microbiology*, 7. [Online] DOI: 10.3389/fmicb.2016.00417.
- Balouiri, M., Sadiki, M. and Ibsouda, S.K. (2016), "Methods for in vitro evaluating antimicrobial activity: A review", *Journal of Pharmaceutical Analysis*, 6(2), pp.71-79. [Online] DOI: <https://doi.org/10.1016/j.jpha.2015.11.005>.
- Bhattamisra, S. K., Kuean, C. H., Chieh, L. B., Yan, V. L. Y., Lee, C. K., Hooi, L. P., Shyan, L. P., Liew, Y. K., Candasamy, M. and Sahu, P. S. (2018), "Antibacterial activity of geraniol in combination with standard antibiotics against *Staphylococcus aureus*, *Escherichia coli* and *Helicobacter pylori*", *Natural Product Communications. SAGE Publications Inc*, 13(7), pp791-793. [Online] DOI: 10.1177/1934578X1801300701.
- Bouyahya, A., Abrini, J., Dakka, N. and Bakri, Y. (2019), "Essential oils of *Origanum compactum* increase membrane permeability, disturb cell membrane integrity, and suppress quorum-sensing phenotype in bacteria", *Journal of Pharmaceutical Analysis*, 9(5), pp.301-311. [Online] DOI: <https://doi.org/10.1016/j.jpha.2019.03.001>.
- Breijyeh, Z., Jubeh, B. and Karaman, R. (2020), "Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it", *Molecules*, 25(6), p. 1340. [Online]DOI: 10.3390/molecules25061340.
- Brugger, S. D., Bomar, L. and Lemon, K. P. (2016), "Commensal-pathogen interactions along the human nasal passages", *PLOS Pathogens*, 12(7). [Online] DOI: 10.1371/journal.ppat.1005633.
- Brugnera, D.F., Oliveira, M.M.M and Piccoli, R.H. (2011), "Essential oils of *Cymbopogon* sp. In the Control of Foodborne Pathogenic Bacteria", *Alimentos e Nutricao [Brazilian Journal of Food and Nutrition]*, 22(3), pp.339-343. [Online] Available at: <https://pdfs.semanticscholar.org/ca13/a6ecbe3d1f18ace4503ab5ef7de8c36f4777.pdf>.(Accessed:26 August 2020).
- Capasso, C. and Supuran, C. T. (2014), "Sulfa and trimethoprim-like drugs – antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors", *Journal of Enzyme Inhibition and Medicinal Chemistry*, 29(3), pp. 379-387. [Online] DOI: 10.3109/14756366.2013.787422.
- Chai, T.-T., Ong, H.-C., Ooh, K.-F., Wong, F.-C. and Sit, N.-W. (2014), "High performance liquid chromatography profiling of health-promoting phytochemicals and evaluation of antioxidant, anti-lipoxygenase, iron chelating and anti-glucosidase activities of wetland macrophytes", *Pharmacognosy Magazine*, 10(39), pp.

443. [Online] DOI: 10.4103/0973-1296.139767.
- Cheesman, M. J., Ilanko, A., Blonk, B. and Cock, I. E. (2017), "Developing new antimicrobial therapies: are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution?", *Pharmacognosy Reviews*, 11(22), pp. 57–72. [Online] DOI: 10.4103/phrev.phrev_21_17.
- De Castro Spadari, C., Vila, T., de Moraes Barroso, V. and Ishida, K. (2020), "New targets for the development of antifungal agents", *Reference Module in Life Sciences*. Elsevier. [Online] DOI: 10.1016/B978-0-12-809633-8.21026-1.
- De Toledo, L., Ramos, M., Spósito, L., Castilho, E., Pavan, F., Lopes, É., Zocolo, G., Silva, F., Soares, T., dos Santos, A., Bauab, T. and De Almeida, M. (2016), "Essential oil of *Cymbopogon nardus* (L.) Rendle: A strategy to combat fungal infections caused by *Candida* species", *International Journal of Molecular Sciences*, 17(8), p.1252. [Online] DOI: 10.3390/ijms17081252.
- De Zoysa, M. H. N., Rathnayake, H., Hewawasam, R. P. and Gaya Bandara Wijayarathne, W. M. D. (2019), "Determination of in vitro antimicrobial activity of five sri lankan medicinal plants against selected human pathogenic bacteria", *International Journal of Microbiology*, 2019, pp. 1–8. [Online] DOI: 10.1155/2019/7431439.
- Ekins, S., Mestres, J. and Testa, B. (2007), "in silico pharmacology for drug discovery: applications to targets and beyond", *British Journal of Pharmacology*, 152(1), pp. 21–37. [Online] DOI: 10.1038/sj.bjp.0707306.
- Eliopoulos, G. M. and Huovinen, P. (2001), "Resistance to trimethoprim-sulfamethoxazole", *Clinical Infectious Diseases*, 32(11), pp. 1608–1614. [Online] DOI: 10.1086/320532.
- Elisha, I. L., Botha, F. S., McGaw, L. J. and Eloff, J. N. (2017), "The antibacterial activity of extracts of nine plant species with good activity against *Escherichia coli* against five other bacteria and cytotoxicity of extracts", *BMC Complementary and Alternative Medicine*, 17. DOI: 10.1186/s12906-017-1645-z.
- El-Nahhal, Y., EL-dahdouh, N., Hamdona, N. and Alshanti, A. (2016), "Toxicological data of some antibiotics and pesticides to fish, mosquitoes, cyanobacterial mats and to plants", *Data in Brief*, 6, pp. 871–880. [Online] DOI: 10.1016/j.dib.2016.01.051.
- Ezeonu, C. S. and Ejikeme, C. M. (2016), "Qualitative and quantitative determination of phytochemical contents of indigenous nigerian softwoods", *New Journal of Science*, 2016, pp. 1–9. [Online] DOI: 10.1155/2016/5601327.
- Fairhurst, R. M. and Wellems, T. E. (2015), "Malaria (*Plasmodium* species)", in Bennett, J.E., Dolin, R and Blaser, M.J. (Ed.) , *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, Elsevier, pp. 3070-3090.e9. [Online] DOI: 10.1016/B978-1-4557-4801-3.00276-9.
- Foster, T.J. (2017), "Antibiotic resistance in *Staphylococcus aureus*. Current status and future prospects", *FEMS Microbiology Reviews*, 41(3), pp.430–449. [Online] DOI: <https://doi.org/10.1093/femsre/flux007>.
- Fratamico, P.M., DebRoy, C., Liu, Y., Needleman, D.S., Baranzoni, G.M. and Feng, P. (2016), "Advances in molecular serotyping and subtyping of *Escherichia coli*", *Frontiers in Microbiology*, 7. [Online] DOI: 10.3389/fmicb.2016.00644.
- Ganguangco, L. M., Alejandria, M., Henson, K. E., Alfaraz, L., Ata, R. M., Lopez, M. and Saniel, M. (2015), "Prevalence and risk factors for trimethoprim-sulfamethoxazole-resistant *Escherichia coli* among women with acute uncomplicated urinary tract infection in a developing country", *International Journal of Infectious Diseases*, 34, pp. 55–60. [Online] DOI: 10.1016/j.ijid.2015.02.022.
- Gardete, S. and Tomasz, A. (2014), "Mechanisms of vancomycin resistance in *Staphylococcus aureus*", *Journal of Clinical Investigation*, 124(7), pp.2836–2840. [Online] DOI: 10.1172/JCI68834.
- Guo, Y., Song, G., Sun, M., Wang, J. and Wang, Y. (2020), "Prevalence and therapies of antibiotic-resistance in *Staphylococcus aureus*", *Frontiers in*

- Cellular and Infection Microbiology*, 10, p. 107. [Online] DOI: 10.3389/fcimb.2020.00107.
- Jafri, S.A., Qasim, M., Masoud, M.S., Rahman, M.U., Izhar, M. and Kazmi, S. (2014), "Antibiotic resistance of *E. coli* isolates from urine samples of Urinary Tract Infection (UTI) patients in Pakistan", *Bioinformation*, 10(7), pp.419–422. [Online]DOI: 10.6026/97320630010419.
- Kačaniová, M., Terentjeva, M., Vukovic, N., Puchalski, C., Roychoudhury, S., Kunová, S., Klüga, A., Tokár, M., Kluz, M. and Ivanišová, E. (2017), "The antioxidant and antimicrobial activity of essential oils against *Pseudomonas* spp. isolated from fish", *Saudi Pharmaceutical Journal*, 25(8), pp.1108–1116. [Online]DOI: 10.1016/j.jsps.2017.07.005.
- Kamal, H. Z. A., Ismail, T. N. N. T., Arief, E. M. and Ponnuraj, K. T. (2020), "Antimicrobial activities of citronella (*Cymbopogon nardus*) essential oil against several oral pathogens and its volatile compounds", *Padjadjaran Journal of Dentistry*, 32(1), pp. 1–7. [Online] DOI: 10.24198/pjd.vol32no1.24966.
- Kamari, F., Taroq, A., Atki, Y., Aouam, I., Oumokhtar, B., Lyoussi, B. and Abdellaoui, A. (2018), "Cymbopogon nardus L. Essential Oil: Phytochemical Screening and its Antibacterial Activity against Clinical Bacteria Responsible for Nosocomial Infections in Neonatal Intensive Care", *International Journal of Pharmaceutical Sciences Review and Research*, 50(1), pp.14–17. [Online] Available at: <http://globalresearchonline.net/journalcontents/v50-1/03.pdf> (Accessed 16 August 2020).
- Kapoor, G., Saigal, S. and Elongavan, A. (2017), "Action and resistance mechanisms of antibiotics: A guide for clinicians", *Journal of Anaesthesiology Clinical Pharmacology*, 33(3), p. 300. [Online] DOI: 10.4103/joacp.JOACP_349_15.
- Karczmarczyk, M., Martins, M., Quinn, T., Leonard, N. and Fanning, S. (2011), "Mechanisms of fluoroquinolone resistance in *Escherichia coli* isolates from food-producing animals", *Applied and Environmental Microbiology*, 77(20), pp. 7113–7120. [Online] DOI: 10.1128/AEM.00600-11.
- Kim, K.S. (2016), "Human Meningitis-Associated *Escherichia coli*", *EcoSal Plus*, 7(1). [Online]DOI: 10.1128/ecosalplus.ESP-0015-2015.
- Koohsari, H., Ghaemi, E., Sadegh Sheshpoli, M., Jahedi, M., & Zahiri, M. (2015), "The investigation of antibacterial activity of selected native plants from North of Iran", *Journal of Medicine and Life*, 8(2), 38–42. [Online] Available at: <https://pubmed.ncbi.nlm.nih.gov/28255395/> (Accessed: 26 August 2020).
- Kuraitis, D. and Williams, L. (2018), "Decolonization of *Staphylococcus aureus* in healthcare: A dermatology perspective", *Journal of Healthcare Engineering*. [Online]DOI: <https://www.hindawi.com/journals/jhe/2018/2382050/>.
- Lee, D.S., Lee, S.-J. and Choe, H.-S. (2018), "Community-acquired urinary tract infection by *Escherichia coli* in the era of antibiotic resistance", *BioMed Research International*, [online] 2018, pp.1–14 Hindawi. [Online] Available at: <https://www.hindawi.com/journals/bmri/2018/7656752/> (Accessed: 22 April 2019).
- Llarrull, L. I., Fisher, J. F. and Mobashery, S. (2009), "Molecular basis and phenotype of methicillin resistance in *Staphylococcus aureus* and insights into new β -lactams that meet the challenge", *Antimicrobial Agents and Chemotherapy*, 53(10), pp. 4051–4063. [Online] DOI: 10.1128/AAC.00084-09.
- Loomba, P., Taneja, J. and Mishra, B. (2010), "Methicillin and vancomycin resistant *S. aureus* in hospitalized patients", *Journal of Global Infectious Diseases*, 2(3), p. 275. [Online] DOI: 10.4103/0974-777X.68535.
- Lopez-Romero, J. C., González-Ríos, H., Borges, A. and Simões, M. (2015), "Antibacterial effects and mode of action of selected essential oils components against *Escherichia coli* and *Staphylococcus aureus*", *Evidence-Based Complementary and Alternative Medicine*, Hindawi. Available at:

- <https://doi.org/10.1155/2015/795435>. (Accessed: 12 April 2020).
- Masters, P.A., O'Bryan, T.A., Zurlo, J., Miller, D.Q. and Joshi, N. (2003), "Trimethoprim-sulfamethoxazole revisited", *Archives of internal medicine*, 163(4), pp.402–10. [Online] DOI: 10.1001/archinte.163.4.402.
- Muttalib, S.A., Edros, R., Nor Azah, M. A., Kutty, R.V. (2018), "A Review: The extraction of active compound from *Cymbopogon* sp. and its potential for medicinal applications", *International journal of engineering technology and sciences*, 5(1). [Online] Available at: <http://dx.doi.org/10.15282/ijets.5.1.2018.1008>. (Accessed: 13 April 2020).
- Park, Y.S., Adams-Haduch, J.M., Shutt, K.A., Yarabinec, D.M., Johnson, L.E., Hingwe, A., Lewis, J.S., Jorgensen, J.H. and Doi, Y. (2012), "Clinical and Microbiologic Characteristics of Cephalosporin-Resistant *Escherichia coli* at Three Centers in the United States", *Antimicrobial Agents and Chemotherapy*, 56(4), pp.1870–1876. [Online] DOI: 10.1128/AAC.05650-11.
- Parker, D. and Prince, A. (2011), "Immunopathogenesis of *Staphylococcus aureus* pulmonary infection", *Seminars in Immunopathology*, 34(2), pp.281–297. [Online] DOI: 10.1007/s00281-011-0291-7.
- Peirano, V., Bianco, M.N., Navarro, A., Schelotto, F. and Varela, G. (2018), "Diarrheagenic *Escherichia coli* associated with acute gastroenteritis in children from Soriano, Uruguay", *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2018, pp.1–8. [Online] DOI: <https://doi.org/10.1155/2018/8387218>.
- Pontes, E.K.U., Melo, H.M., Nogueira, J.W.A., Firmino, N.C.S., de Carvalho, M.G., Catunda Júnior, F.E.A. and Cavalcante, T.T.A. (2018), "Antibiofilm activity of the essential oil of citronella (*Cymbopogon nardus*) and its major component, geraniol, on the bacterial biofilms of *Staphylococcus aureus*", *Food Science and Biotechnology*, 28(3), pp.633–639. [Online] DOI: 10.1007/s10068-018-0502-2.
- Rağbetli, C., Parlak, M., Bayram, Y., Guducuoglu, H. and Ceylan, N. (2016), "Evaluation of antimicrobial resistance in *Staphylococcus aureus* isolates by years", *Interdisciplinary Perspectives on Infectious Diseases*, 2016, pp. 1–4. [Online] DOI: 10.1155/2016/9171395.
- Rai, Y., Pathak, R., Kumari, N., Sah, D. K., Pandey, S., Kalra, N., Soni, R., Dwarakanath, B. S. and Bhatt, A. N. (2018), "Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition", *Scientific Reports*, 8(1), pp. 1–15. [Online] DOI: 10.1038/s41598-018-19930-w.
- Sabuna, C., Wihandoyo, Harimurti, S. and Nurcahyo, R.W. (2018), "Effects of *Citronella* (*Cymbopogon nardus*) ethanol extracts and distillate dried powder waste on inhibition of *Ascaridia galli* development", *International Journal of Poultry Science*, 17(6), pp.262–267. [Online] DOI: 10.3923/ijps.2018.262.267.
- Sannasiddappa, T.H., Costabile, A., Gibson, G.R. and Clarke, S.R. (2011), "The Influence of *Staphylococcus aureus* on gut microbial ecology in an in Vitro continuous culture human colonic model system", *PLOS ONE*, 6(8). [Online] DOI: <https://doi.org/10.1371/journal.pone.0023227>.
- Schweizer, M. L., Furuno, J. P., Harris, A. D., Johnson, J. K., Shardell, M. D., McGregor, J. C., Thom, K. A., Cosgrove, S. E., Sakoulas, G. and Perencevich, E. N. (2011), "Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible *Staphylococcus aureus* bacteremia", *BMC Infectious Diseases*, 11(1), p. 279. [Online] DOI: 10.1186/1471-2334-11-279.
- Singh, Kushagri, Mishra, A., Sharma, D. and Singh, Kavita (2019), "Antiviral and Antimicrobial Potentiality of Nano Drugs", in Mohapatra, S. S., Ranjan, S., Dasgupta, N., Mishra, R. K., and Thomas, S. (eds) *Applications of*

- Targeted Nano Drugs and Delivery Systems. Elsevier (*Micro and Nano Technologies*), pp. 343–356. DOI: 10.1016/B978-0-12-814029-1.00013-2.
- Šiširak, M., Zvizdić, A. and Hukić, M. (2010), “Methicillin-resistant *Staphylococcus aureus* (MRSA) as a cause of nosocomial wound infections”, *Bosnian Journal of Basic Medical Sciences*, 10(1), pp. 32–37. [Online] DOI: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596608/>
- Soto, S. M. (2013), “Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm”, *Virulence*, 4(3), pp. 223–229. [Online] DOI: 10.4161/viru.23724.
- Sritabutra, D. and Soonwera, M. (2013), “Repellent activity of herbal essential oils against *Aedes aegypti* (Linn.) and *Culex quinquefasciatus* (Say.)”, *Asian Pacific Journal of Tropical Disease*, 3(4), pp.271–276. [Online]DOI: 10.1016/S2222-1808(13)60069-9.
- Stohr, J. J. M., Kluytmans-van den Bergh, M. F. Q., Verhulst, C. J. M. M., Rossen, J. W. A. and Kluytmans, J. A. J. W. (2020), “Development of amoxicillin resistance in *Escherichia coli* after exposure to remnants of a non-related phagemid-containing *E. coli*: an exploratory study”, *Antimicrobial Resistance & Infection Control*, 9(1), p. 48.[Online] DOI: 10.1186/s13756-020-00708-7.
- Stone, M. D., Bryant, Z., Crisona, N. J., Smith, S. B., Vologodskii, A., Bustamante, C. and Cozzarelli, N. R. (2003), “Chirality sensing by *Escherichia coli* topoisomerase IV and the mechanism of type II topoisomerases”, *Proceedings of the National Academy of Sciences*, 100(15), pp. 8654–8659. [Online] DOI: 10.1073/pnas.1133178100.
- Subramanian, P., Takwa, C.W.I.C.W. and Zubair, N.E.A (2015), “Chemical composition and antibacterial activity of essential oil of *Cymbopogon citratus* and *Cymbopogon nardus* against *Enterococcus faecalis*”, *International Journal of Biosciences (IJB)*, 6(9), pp.9–17. [Online]DOI: 10.12692/ijb/6.9.9-17.
- Tanih, N.F., Sekwadi, E., Ndip, R.N. and Bessong, P.O. (2015), “Detection of Pathogenic *Escherichia coli* and *Staphylococcus aureus* from cattle and pigs slaughtered in abattoirs in Vhembe District, South Africa”, *The Scientific World Journal*, 2015, pp.1–8. [Online]DOI: 10.1155/2015/195972.
- Terahara, F. and Nishiura, H. (2019), “Fluoroquinolone consumption and *Escherichia coli* resistance in Japan: an ecological study”, *BMC Public Health*, 19. [Online] DOI: 10.1186/s12889-019-6804-3.
- Tong, S.Y.C., Davis, J.S., Eichenberger, E., Holland, T.L. and Fowler, V.G. (2015), “*Staphylococcus aureus* Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management”, *Clinical Microbiology Reviews*, 28(3), pp.603–661. [Online]DOI:10.1128/CMR.00134-14.
- Treangen, T.J., Maybank, R.A., Enke, S., Friss, M.B., Diviak, L.F., Karaolis, D.K.R., Koren, S., Ondov, B., Phillippy, A.M., Bergman, N.H. and Rosovitz, M.J. (2014), “Genome sequence of the quality control strain *Staphylococcus aureus* subsp. *aureus* ATCC 25923”, *Genome Announcements*, 2(6). [Online]DOI: 10.1128/genomeA.01110-14.
- Trombetta, D., Castelli, F., Sarpietro, M. G., Venuti, V., Cristani, M., Daniele, C., Saija, A., Mazzanti, G. and Bisignano, G. (2005), “Mechanisms of antibacterial action of three monoterpenes”, *Antimicrobial Agents and Chemotherapy*, 49(6), pp. 2474–2478. [Online] DOI: 10.1128/AAC.49.6.2474-2478.2005.
- Velkov, T., Bergen, P. J., Lora-Tamayo, J., Landersdorfer, C. B. and Li, J. (2013), “PK/PD models in antibacterial development”, *Current Opinion in Microbiology*, 16(5), pp. 573–579. [Online] DOI: 10.1016/j.mib.2013.06.010.

- Ventola, C. L. (2015), "The Antibiotic Resistance Crisis", *Pharmacy and Therapeutics*, 40(4), pp. 277–283 PMC. [Online]Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/> (Accessed: 12 April 2020).
- Vranic, S. and Uzunovic, A. (2016), "Antimicrobial resistance of *Escherichia coli* strains isolated from urine at outpatient population: a single laboratory experience", *Materia Socio Medica*, 28(2), p.121. [Online]DOI: 10.5455/msm.2016.28.121-124.
- Webber, M. A. and Piddock, L. J. V. (2003), "The importance of efflux pumps in bacterial antibiotic resistance", *Journal of Antimicrobial Chemotherapy*, 51(1), pp. 9–11. [Online] DOI: 10.1093/jac/dkg050.
- Wei, L.S. and Wee, W. (2013), "Chemical composition and antimicrobial activity of *Cymbopogon nardus* citronella essential oil against systemic bacteria of aquatic animals", *Iranian Journal of Microbiology*, 5(2), pp.147–152 NCBI. [Online]Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696851/> (Accessed 14 April 2020).
- Wibowo, D. P., Febriani, Y., Riasari, H. and Aulifa, D. L. (2018), "Chemical composition, antioxidant and antibacterial activities of the essential oils of medicinal plant *Cymbopogon nardus* from Lembang West Java", *Research Journal of Chemistry and Environment*, 22, pp.1-4 ResearchGate.[Online]Available at: <https://worldresearchersassociation.com/specialissuejan2018/1.pdf> (Accessed: 14April 2020).
- Zeng, X. and Lin, J. (2013), "Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria", *Frontiers in Microbiology*, 4. [Online] DOI: <https://doi.org/10.3389/fmicb.2013.00128>.